METHODS OF TREATING USING ANTI-CD123 IMMUNOCONJUGATES Russian patent published in 2024 - IPC A61K31/5513 A61K51/00 A61K39/395 A61K47/55 C07K16/28 A61P35/02 

FIELD: medicine.

SUBSTANCE: group of inventions relates to a method of treating a hematologic malignant tumour in humans. Method of treating a hematologic malignant tumour in a human, comprising administering to a subject an anti-CD123 immunoconjugate containing an anti-CD123 antibody or an antigen-binding fragment thereof, linked to an indolinobenzodiazepine (IGN) DNA alkylator, wherein the immunoconjugate is administered in dose of 0.045 mg/kg to less than 0.3 mg/kg, and wherein said anti-CD123 antibody or its antigen-binding fragment contains: a. CDR1 of the variable region of the heavy chain containing the amino acid sequence SEQ ID NO: 5; CDR2 of the variable region of the heavy chain containing the amino acid sequence SEQ ID NO: 6; and a heavy chain variable region CDR3 comprising the amino acid sequence SEQ ID NO: 7; and b. CDR1 of the light chain variable region containing the amino acid sequence SEQ ID NO: 8; CDR2 of the light chain variable region containing the amino acid sequence SEQ ID NO: 9; and a light chain variable region CDR3 comprising the amino acid sequence SEQ ID NO: 10. Method of treating a hematologic malignant tumour in a human, comprising administering to a subject an anti-CD123 immunoconjugate containing an anti-CD123 antibody or an antigen-binding fragment thereof, linked to an indolinobenzodiazepine (IGN) DNA alkylator, wherein from 0.015 mg/kg to 0.09 mg/kg of the immunoconjugate is administered three times in 21-day cycle, and wherein said anti-CD123 antibody or its antigen-binding fragment contains said heavy chain variable regions having said amino acid sequence. Method of treating a hematologic malignant tumour in a human, comprising administering to a subject an anti-CD123 immunoconjugate containing an anti-CD123 antibody or an antigen-binding fragment thereof, associated with an indolinobenzodiazepine (IGN) DNA alkylator, wherein from 0.015 mg/kg to 0.09 mg/kg of the immunoconjugate is administered twice in 21-day cycle, and wherein said anti-CD123 antibody or antigen-binding fragment thereof also comprises said variable heavy chain regions having said amino acid sequence.

EFFECT: use of the group of inventions provides the use of therapeutically effective modes of administration, which minimize undesirable side effects in treating hematologic malignant tumours in humans.

53 cl, 7 dwg, 7 tbl, 4 ex